Dominic KingSmith - Crescita Therapeutics VP Devel

All Insiders . USA . 
Stock . Crescita Therapeutics . Stakeholders . Insider . Dominic KingSmith
CRRTF Stock  USD 0.45  0.00  0.00%   

Insider

Dominic KingSmith is VP Devel of Crescita Therapeutics
Phone905 673 4297
Webhttps://www.crescitatherapeutics.com

Crescita Therapeutics Management Efficiency

The company has return on total asset (ROA) of 0.0227 % which means that it generated a profit of $0.0227 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0318 %, meaning that it generated $0.0318 on every $100 dollars invested by stockholders. Crescita Therapeutics' management efficiency ratios could be used to measure how well Crescita Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Crescita Therapeutics has accumulated 1.71 M in total debt with debt to equity ratio (D/E) of 0.09, which may suggest the company is not taking enough advantage from borrowing. Crescita Therapeutics has a current ratio of 3.04, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Crescita Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Crescita Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Crescita Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Crescita to invest in growth at high rates of return. When we think about Crescita Therapeutics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Man MBAAdagene
47
Kenneth CundyAnebulo Pharmaceuticals
65
Morgan ConnPharvaris BV
55
Jc MDAdagene
59
Benjamin DakeAerovate Therapeutics
48
MD MPHMediciNova
56
Rex CFAAnebulo Pharmaceuticals
64
Kyle BreidenstinePepGen
N/A
Donna DeaAerovate Therapeutics
N/A
Winston MBAPmv Pharmaceuticals
48
Niels SvenstrupPepGen
54
James McArthurPepGen
62
Robyn SweinhartRezolute
N/A
Yuichi MDMediciNova
74
Guizhong LiuAdagene
53
MBA MRAerovate Therapeutics
62
George EldridgeAerovate Therapeutics
61
Seth LewisMolecular Partners AG
N/A
Caroline GodfreyPepGen
N/A
Alexander ZurcherMolecular Partners AG
49
Timothy MBAAerovate Therapeutics
62
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada. Crescita Therapeutics is traded on OTC Exchange in the United States. Crescita Therapeutics [CRRTF] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

Return On Equity0.0318
Return On Asset0.0227

Crescita Therapeutics Leadership Team

Elected by the shareholders, the Crescita Therapeutics' board of directors comprises two types of representatives: Crescita Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Crescita. The board's role is to monitor Crescita Therapeutics' management team and ensure that shareholders' interests are well served. Crescita Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Crescita Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Dominic KingSmith, VP Devel
Francois Lafortune, Ex GM

Crescita Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Crescita Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.0318
Return On Asset0.0227
Profit Margin0.03 %
Operating Margin0.04 %
Current Valuation3.64 M
Shares Outstanding20.4 M
Shares Owned By Insiders7.30 %
Price To Earning490.00 X
Price To Book0.66 X
Price To Sales0.41 X

Currently Active Assets on Macroaxis

TITANTitan Company Limited
UUnity Software
PAYCPaycom Soft
HBIHanesbrands
STLDSteel Dynamics

Other Information on Investing in Crescita Pink Sheet

Crescita Therapeutics financial ratios help investors to determine whether Crescita Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Crescita with respect to the benefits of owning Crescita Therapeutics security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY